Skip to content

Influence of Therapeutic Education in Patients With Joint Inflammation Treated With a Biological Treatment

Impact of a Therapeutic Education Program in Patients With Non-radiological Spondyloarthritis Treated With Anti-tumor Necrosis Factor (TNF)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03360864
Acronym
ALSASP
Enrollment
110
Registered
2017-12-04
Start date
2020-01-16
Completion date
2023-01-16
Last updated
2020-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-radiographic Spondyloarthritis

Keywords

Therapeutic education

Brief summary

To describe, with a patient reported score (BIOSECURE), the influence of an approved therapeutic education program (TEP) in patients with joint inflammation requiring a biological treatment initiation. The hypothesis is that patients attending the TEP will display better cognitive and adaptation competences than patients with no TEP. Patient's reported quality of life, disease related stress management, treatment adherence, socio-demographic factors, biological home administration modalities and if the biologic treatment is maintained at 12 months, will also be described.

Interventions

OTHEREducation program

Patient will participate to a education program.

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Non-radiological spondyloarthritis diagnosis (ASAS criteria) * Anti-TNFalpha biological treatment initiation required * Adult patient (age\>18years) * Capacity to understand self-questionnaires and address questions * Patient accepting to attend a therapeutic education program (TEP)

Exclusion criteria

* Previous Anti-TNFalpha biological treatment * Previous attendance to a TEP concerning biological or spondyloarthritis * Contraindication to Anti-TNFalpha treatment * Associated and unbalanced diseases

Design outcomes

Primary

MeasureTime frameDescription
BIOSECURE patient self-questionnaireChange from Baseline Biosecure's score at 6 months and at 12 month after biological treatment initiationPatients will address questions and role play scenario evaluating cognitive and adaptive competences. The Biosecure score is between 0 and 100.

Countries

France

Contacts

Primary ContactChristelle SORDET, MD
christelle.sordet@chru-strasbourg.fr3 88 12 81 16

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026